Additionally, the 36-month beta value for LXRX is 1.20. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 3 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for LXRX is 304.81M and currently, short sellers hold a 9.40% ratio of that float. The average trading volume of LXRX on November 19, 2024 was 3.16M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
LXRX) stock’s latest price update
The stock of Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) has decreased by -7.20 when compared to last closing price of 0.98.Despite this, the company has seen a loss of -28.74% in its stock price over the last five trading days. seekingalpha.com reported 2024-11-12 that Start Time: 17:00 January 1, 0000 5:55 PM ET Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q3 2024 Earnings Call November 12, 2024, 17:00 PM ET Company Participants Mike Exton – CEO and Director Tom Garner – SVP and Chief Commercial Officer Craig Granowitz – SVP and Chief Medical Officer Alan Main – EVP, Innovation and Chemical Sciences Lisa DeFrancesco – Head, IR and Corporate Strategy Conference Call Participants Andrew Tsai – Jeffries Joseph Stringer – Needham and Company Joe Pantginis – H.C. Wainwright Yigal Nochomovitz – Citigroup Roanna Ruiz – Leerink Partners Operator Good day, and welcome to the Lexicon Pharmaceuticals Third Quarter 2024 Results Conference Call.
LXRX’s Market Performance
Lexicon Pharmaceuticals Inc (LXRX) has experienced a -28.74% fall in stock performance for the past week, with a -54.98% drop in the past month, and a -46.45% drop in the past quarter. The volatility ratio for the week is 8.86%, and the volatility levels for the past 30 days are at 9.21% for LXRX. The simple moving average for the past 20 days is -37.83% for LXRX’s stock, with a -52.00% simple moving average for the past 200 days.
Analysts’ Opinion of LXRX
Many brokerage firms have already submitted their reports for LXRX stocks, with H.C. Wainwright repeating the rating for LXRX by listing it as a “Buy.” The predicted price for LXRX in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on June 17, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see LXRX reach a price target of $5. The rating they have provided for LXRX stocks is “Outperform” according to the report published on April 30th, 2024.
Jefferies gave a rating of “Hold” to LXRX, setting the target price at $3 in the report published on March 07th of the previous year.
LXRX Trading at -43.16% from the 50-Day Moving Average
After a stumble in the market that brought LXRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.74% of loss for the given period.
Volatility was left at 9.21%, however, over the last 30 days, the volatility rate increased by 8.86%, as shares sank -56.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.79% lower at present.
During the last 5 trading sessions, LXRX fell by -28.74%, which changed the moving average for the period of 200-days by -54.29% in comparison to the 20-day moving average, which settled at $1.4558. In addition, Lexicon Pharmaceuticals Inc saw -40.85% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LXRX starting from COATS LONNEL, who proposed sale 300,000 shares at the price of $1.60 back on Aug 15 ’24. After this action, COATS LONNEL now owns shares of Lexicon Pharmaceuticals Inc, valued at $480,000 using the latest closing price.
Stock Fundamentals for LXRX
Current profitability levels for the company are sitting at:
- -40.44 for the present operating margin
- 0.88 for the gross margin
The net margin for Lexicon Pharmaceuticals Inc stands at -41.16. The total capital return value is set at -0.74. Equity return is now at value -135.14, with -71.91 for asset returns.
Based on Lexicon Pharmaceuticals Inc (LXRX), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -2.08. The debt to equity ratio resting at 0.56. The interest coverage ratio of the stock is -26.33.
Currently, EBITDA for the company is -163.46 million with net debt to EBITDA at -0.32. When we switch over and look at the enterprise to sales, we see a ratio of 75.19. The receivables turnover for the company is 1.8for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.45.
Conclusion
In conclusion, Lexicon Pharmaceuticals Inc (LXRX) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
